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In this issue, Montalvão and colleagues [1] present important information on the value of 
heat treatment of specimens for inhibitor measurement in hemophilia A patients undergoing 
immune tolerance induction therapy (ITI). Inhibitors, antibodies directed against infused 
treatment products, are the most significant complication of hemophilia therapy today, 
occurring in up to 30% of severe patients during their initial exposures to factor VIII (FVIII) 
replacement. Risk of inhibitor development persists through the lifespan, with a second peak 
of inhibitors occurring later in life [2], and patients with all severities of hemophilia A 
develop inhibitors [3]. Annual testing is recommended for all patients, with more frequent 
monitoring for those at highest risk [4]. In addition to clinical use of the inhibitor test in 
detection of new inhibitors, selection of therapy, and monitoring for successful inhibitor 
eradication, this test is also the key endpoint measurement for evaluation of product safety, 
assessment of population trends, and studies of inhibitor risk factors. We have previously 
introduced modifications to traditional inhibitor tests to improve their usefulness for these 
purposes by minimizing false negative and false positive results [5,6].
The first standardized method for measuring hemophilic inhibitors, the Bethesda assay, was 
described in 1975 [7], with reagent modifications to improve its performance added in 1995 
[8], producing what has come to be called the Nijmegen–Bethesda assay. In the past 20 
years, however, the usefulness of these assays has been compromised by changes in 
hemophilia treatment. Patients receiving prophylactic therapy, by design, have factor present 
at all times and must refrain from treating to “wash out” their factor prior to undergoing 
traditional inhibitor tests. Presence of factor in the test specimen may result in failure to 
detect low titer inhibitors and produce a false negative result [5]. Patients undergoing ITI 
present similar problems due to frequent FVIII infusions.
Allain and Frommel [9] demonstrated that heating of inhibitor specimens to 56° for 30 min 
destroyed the FVIII present without affecting the antibody. Others have suggested use of 
this method, without documenting its effectiveness [10–12]. We provided data that the 
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heating step removed both FVIII activity and FVIII antigen from plasma and showed that 
transition from a negative to a positive test result occurred occasionally in specimens from 
previously inhibitor-negative patients and frequently in those with a history of inhibitor [5]. 
Recently, Batty and colleagues have seen a more significant effect in patients with acquired 
hemophilia, in whom the detection rate for inhibitors rose from 5% to 51% when pre-
analytical heat treatment was used [13]. Montalvão et al. [1] have now shown that this 
method also improves detection of inhibitors during ITI. In 3 of their 5 patients on ITI, 
negative specimens became positive after heating at some point in their monitoring, and the 
mean inhibitor titer for 68 ITI specimens increased 3-fold after heating. They noted that 
these changes could affect the prescribed course, and thus the success, of therapy.
A heating step of 56 °C for 30 min, as described by Allain and Frommel [9], was used in 
Montalvão et al. [1] and our studies [5,6]; others have used regimens with temperatures up 
to 58 °C and times as long as 90 min [12,13]. The more rigorous heating step may result in 
loss of FVIII antibodies measured by ELISA in some specimens [13] and cannot be 
recommended. Since the shorter time and lower temperature results in FVIII destruction and 
is known to preserve antibodies, it is preferable for this purpose.
Heat treatment of specimens has already been adopted by some laboratories to allow 
inhibitor testing without withholding factor infusions, eliminating one barrier to routine 
screening. Another barrier, however, is the high false positive rate of the assay and the risk 
of over-diagnosis of inhibitors. Proficiency testing internationally has documented 
coefficients of variation as high as 50% between laboratories and false positive rates up to 
32% [14]. This methodologic variation is due primarily to differences in methods and 
reagents among laboratories. Additional sources of variability in clinical testing include the 
presence in patient plasma of substances such as heparin or non-specific inhibitors that 
interfere in clot-based inhibitor assays. Recently, up to 25% of low-titer inhibitor plasmas 
(<2 Nijmegen–Bethesda units) have been shown to lack detectable anti-FVIII antibodies 
[6,15], and such false positive inhibitors have influenced the results of clinical trials [15]. 
Recommendations have been made that low titer inhibitors should be repeated for 
confirmation and assessed for reactivity with factor VIII by chromogenic or immunologic 
assays before an inhibitor diagnosis is made [6,15]. Adoption of two steps, use of a standard 
method including heat treatment and confirmation of low positive results, would minimize 
both false negative and false positive results yet allow the detection of inhibitors at low 
titers, before they have major clinical impact and when they can be more easily eradicated. 
These steps have been adopted in a centralized testing program at the Centers for Disease 
Control and Prevention to provide national inhibitor surveillance for people with hemophilia 
in the United States [16].
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